Role of Methane in Glycemic Control
| Status: | Completed |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 10/14/2017 |
| Start Date: | July 2012 |
| End Date: | April 2014 |
Methane Production and Glycemic Regulation in Pre-diabetic Subjects: Role of Methane in Glycemic Control
The purpose of this study is to determine how certain types of bacteria in the human gut may
affect weight gain, and contribute to the development of diabetes.
The investigators initial studies have shown that gut bacteria that produce methane may
directly affect weight gain. These bacteria, called methanogens, produce methane gas as a
byproduct, which can be detected through breath testing. Methane can slow the passage of food
through the intestines, which would allow extra time for uptake and absorption of nutrients
and calories, and might contribute to weight gain. The investigators have also found that
people who have increased levels of methane-producing bacteria in their intestines also have
higher levels of glucose in their blood. Therefore, control of how the body responds to
insulin and uses glucose may be altered in methane-producing individuals.
This research study is designed to test the investigational use of the drugs neomycin and
rifaximin that have been approved by the U.S Food and Drug Administration (FDA). While
neomycin is FDA-approved for treating skin infections, preparing the bowel for surgery, and
hepatic encephalopathy (a condition that occurs when a damaged liver cannot remove the toxins
that a healthy liver normally would), and rifaximin is FDA-approved for treating travelers'
diarrhea, they are not yet approved to be used together for the treatment of methanogens or
obesity.
affect weight gain, and contribute to the development of diabetes.
The investigators initial studies have shown that gut bacteria that produce methane may
directly affect weight gain. These bacteria, called methanogens, produce methane gas as a
byproduct, which can be detected through breath testing. Methane can slow the passage of food
through the intestines, which would allow extra time for uptake and absorption of nutrients
and calories, and might contribute to weight gain. The investigators have also found that
people who have increased levels of methane-producing bacteria in their intestines also have
higher levels of glucose in their blood. Therefore, control of how the body responds to
insulin and uses glucose may be altered in methane-producing individuals.
This research study is designed to test the investigational use of the drugs neomycin and
rifaximin that have been approved by the U.S Food and Drug Administration (FDA). While
neomycin is FDA-approved for treating skin infections, preparing the bowel for surgery, and
hepatic encephalopathy (a condition that occurs when a damaged liver cannot remove the toxins
that a healthy liver normally would), and rifaximin is FDA-approved for treating travelers'
diarrhea, they are not yet approved to be used together for the treatment of methanogens or
obesity.
Inclusion Criteria:
- 18-65 years old with pre-diabetes
- BMI > 25.0
- presence of methane on a breath sample
Exclusion Criteria:
Subjects will be excluded from the study if they exhibit any of the following:
- Diabetes/diabetes medications
- Prokinetic medication
- Pregnancy
- History of bariatric or intestinal surgery (other than cholecystectomy or
appendectomy)
- Unstable thyroid disease
- An active weight loss treatment/plan
- Smoking
- Dietary restrictions (lactose intolerance, vegan etc)
- Other inability to comply with the study procedures, including known allergy to the
study antibiotics (neomycin and rifaximin)
- Active inflammatory bowel disease (celiac, Crohn's disease, ulcerative colitis)
- Antibiotic use in the past month
- Subjects who do not have a microwave (for reheating study meals) and a freezer (for
storing leftovers and stool samples) will be excluded from this study.
- Subjects who have an aspirin sensitivity
- Proton pump inhibitor medications or antacids
- History of bezoar
- Disorders of swallowing
- Suspected strictures, fistulas or physiological GI obstruction
- GI surgery within 3 months
- Severe dysphagia to food or pills
- Diverticulitis
- Subjects who use an implanted or portable electromechanical device such as a cardiac
pacemaker or infusion pump
- Subject who have a peanut allergy
We found this trial at
1
site
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
